Therapeutic monoclonal antibodies

Lancet

Volumn 355, Issue 9205, 2000, Pages 735-740

  Breedveld, F C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; OKT 3; PALIVIZUMAB; RITUXIMAB; TRASTUZUMAB;

ALLOIMMUNITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTHRALGIA; AUTOIMMUNITY; BIOTECHNOLOGY; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG SAFETY; DRUG TARGETING; FEVER; HEADACHE; HUMAN; HYPOTENSION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; REVIEW; STRUCTURE ACTIVITY RELATION; TACHYCARDIA; VOMITING;

EID: 0034716486     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)01034-5     Document Type: Review

References (33)

1. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:1975;495-497.
2. de Geus B., Hendriksen C.F.M. In vivo and in vitro production of monoclonal antibodies: current possibilities and future perspectives. Res Immunol. 149:1998;533-620.
3. Choy E.H., Pitzalis C., Cauli A.et al. Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement: implications for the development of immunotherapeutic dosing regimens. Arthritis Rheum. 39:1996;52-56.
4. Weiner L.M. An overview of monoclonal antibody therapy of cancer. Semin Oncol. 26:1999;41-50.
5. Waldmann H., Cobbold S. How do monoclonal antibodies induce tolerance? A role for infectious tolerance? Annu Rev Immunol. 16:1998;619-644.
6. Alegre M.-L., Collins A.M., Pulito V.L.et al. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanised" OKT3 monoclonal antibody. J Immunol. 148:1992;3461-3468.
7. Vallhonrat H., Williams W.W., Cosimi A.B.et al. In vivo generation of C4d, Bb, iC3v, and SC5b-9 after OKT3 administration in kidney and lung transplant recipients. Transplantation. 67:1999;253-258.
8. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med. 313:1985;337-342.
9. Nashan B., Moore R., Amlot P.et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet. 350:1997;1193-1198.
10. Kahan B.D., Rajagopalan P.R., Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody. Transplantation. 67:1999;276-284.
11. Vincenti F., Lantz M., Birnbaum J.et al. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation. 63:1997;33-38.
12. Nashan B., Light S., Hardie I.R.et al. Reduction of acute renal allograft rejection by daclizumab: Daclizumab Double Therapy Study Group. Transplantation. 67:1999;110-115.
13. Feldmann M., Elliot M.J., Woody J.N., Maini R.N. Anti-tumor necrosis factor-α therapy in rheumatoid arthritis. Adv Immunol. 64:1997;283-351.
14. van Deventer S.J.H. Tumor necrosis factor and CD. Gut. 40:1997;443-448.
15. Elliot M.J., Maini R.N., Feldmann M.et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet. 344:1994;1105-1140.
16. Maini R.N., Breedveld F.C., Kalden J.R.et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41:1998;1552-1563.
17. Maini R.N., St Clair E.W., Breedveld F.C.et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 354:1999;1932-1939.
18. Lipsky P., St Clair E.W., Furst D.et al. 54-week clinical and radiographic results from the ATTRACT trial: a phase III study of infliximab (Remicade™) in patients with active RA despite methotrexate. Arthritis Rheum. 42:1999;401.
19. Breedveld F.C. New tumor necrosis factor-alpha biologic therapies for rheumatoid arthritis. Eur Cytokine Netw. 9:1998;233-238.
20. Targan S.R., Hanauer S.B., van Deventer S.J.H.et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med. 337:1997;1029-1035.
21. Present D.H., Rutgeerts P., Targan S.et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 340:1999;1398-1405.
22. Laughlin P., Grillo-Lopez A.J., Link B.K.et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a 4-dose treatment programme. J Clin Oncol. 16:1998;2824-2833.
23. Czuczman M.S., Grillo-Lopez A.J., White C.A.et al. Treatment of patients with low grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 17:1999;268-276.
24. Dyer M.J.S. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol. 26:1999;52-57.
25. Baselga J., Tripathy D., Mendelsohn J.et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 14:1996;737-744.
26. Slamon D.J., Leyland-Jones B., Shak S.et al. Addition of Herceptin (humanized anti-HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized multinational controlled phase III trial. Proc ASCO. 17:1998;98. (abstr).
27. Baselga J., Tripathy D., Mendelsohn J.et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol. 26:1999;78-83.
28. Topol E.J., Califf R.M., Weisman H.F.et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at 6 months. Lancet. 343:1994;881-886.
29. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularisation. N Engl J Med. 336:1997;1689-1696.
30. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 349:1997;1429-1435.
31. Hamm C.W., Heeschen C., Goldmann B.et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med. 340:1999;1623-1629.
32. Malley R., De Vincenzo J., Ramilo O.et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis. 178:1998;1555-1561.
33. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 102:1998;531-537.